Abbott Laboratories
ABT
$87.77
-$0.61-0.69%
NYSE
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.59% | 5.67% | 6.37% | 5.85% | 5.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.59% | 5.67% | 6.37% | 5.85% | 5.00% |
| Cost of Revenue | 5.81% | 3.57% | 5.55% | 4.01% | 3.31% |
| Gross Profit | 7.20% | 7.35% | 7.03% | 7.34% | 6.37% |
| SG&A Expenses | 10.36% | 5.22% | 5.18% | 5.41% | 5.92% |
| Depreciation & Amortization | -7.78% | -10.44% | -8.92% | -7.55% | -6.21% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.44% | 3.35% | 4.95% | 4.23% | 3.94% |
| Operating Income | 7.24% | 16.33% | 12.78% | 13.37% | 9.97% |
| Income Before Tax | 10.63% | 20.72% | 20.06% | 21.34% | 12.50% |
| Income Tax Expenses | 130.27% | 130.40% | -677.55% | -738.76% | -776.98% |
| Earnings from Continuing Operations | -53.52% | -51.32% | 142.36% | 151.56% | 139.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.52% | -51.32% | 142.36% | 151.56% | 139.82% |
| EBIT | 7.24% | 16.33% | 12.78% | 13.37% | 9.97% |
| EBITDA | 5.10% | 10.47% | 8.06% | 8.22% | 6.14% |
| EPS Basic | -53.68% | -51.46% | 142.33% | 151.80% | 140.76% |
| Normalized Basic EPS | 7.58% | 17.21% | 15.43% | 16.49% | 12.67% |
| EPS Diluted | -53.75% | -51.43% | 142.48% | 151.67% | 140.16% |
| Normalized Diluted EPS | 7.65% | 17.25% | 15.46% | 16.53% | 12.57% |
| Average Basic Shares Outstanding | 0.11% | 0.04% | 0.00% | -0.03% | -0.13% |
| Average Diluted Shares Outstanding | 0.03% | 0.00% | -0.04% | -0.08% | -0.06% |
| Dividend Per Share | 7.02% | 7.14% | 7.27% | 7.41% | 7.55% |
| Payout Ratio | 1.31% | 1.20% | -0.56% | -0.57% | -0.55% |